Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

MergersCorp M&A International

MAY 27, 2025

The Basics At its core, a SPAC is a shell company with no commercial operations, formed solely to raise capital through an Initial Public Offering (IPO) with the express purpose of acquiring an existing private company. What is a SPAC? The investment thesis is often sector-specific. This merger requires shareholder approval.

IPO 52

IPO Mergers and Acquisitions Investors Capital 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. billion acquisition of Catalent, a leader in contract manufacturing for cell and gene therapies, stands out as the largest healthcare deal of 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64